PDT Partners LLC Invests $1.42 Million in TG Therapeutics, Inc. (NASDAQ:TGTX)

PDT Partners LLC purchased a new position in shares of TG Therapeutics, Inc. (NASDAQ:TGTX) during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 60,669 shares of the biopharmaceutical company’s stock, valued at approximately $1,419,000.

Other large investors have also recently added to or reduced their stakes in the company. Captrust Financial Advisors raised its stake in shares of TG Therapeutics by 21.1% during the 3rd quarter. Captrust Financial Advisors now owns 30,327 shares of the biopharmaceutical company’s stock worth $709,000 after buying an additional 5,279 shares in the last quarter. Public Sector Pension Investment Board purchased a new position in TG Therapeutics in the third quarter worth $6,619,000. Zurcher Kantonalbank Zurich Cantonalbank lifted its holdings in TG Therapeutics by 12.0% in the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 31,147 shares of the biopharmaceutical company’s stock valued at $729,000 after acquiring an additional 3,347 shares during the period. Harvest Fund Management Co. Ltd purchased a new stake in shares of TG Therapeutics during the 3rd quarter worth $111,000. Finally, Penserra Capital Management LLC grew its stake in shares of TG Therapeutics by 293.6% during the 3rd quarter. Penserra Capital Management LLC now owns 98,144 shares of the biopharmaceutical company’s stock worth $2,295,000 after purchasing an additional 73,211 shares during the period. 58.58% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other TG Therapeutics news, Director Sagar Lonial sold 5,000 shares of TG Therapeutics stock in a transaction dated Monday, November 11th. The stock was sold at an average price of $30.44, for a total value of $152,200.00. Following the completion of the sale, the director now owns 100,195 shares in the company, valued at $3,049,935.80. The trade was a 4.75 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Corporate insiders own 10.50% of the company’s stock.

Wall Street Analysts Forecast Growth

TGTX has been the subject of several recent analyst reports. B. Riley raised their price objective on shares of TG Therapeutics from $29.00 to $34.00 and gave the company a “buy” rating in a research note on Wednesday, August 7th. HC Wainwright lifted their price target on shares of TG Therapeutics from $49.00 to $55.00 and gave the company a “buy” rating in a research report on Tuesday, November 5th. TD Cowen assumed coverage on TG Therapeutics in a research note on Tuesday, October 29th. They issued a “buy” rating and a $50.00 price objective for the company. The Goldman Sachs Group boosted their target price on TG Therapeutics from $20.00 to $22.00 and gave the stock a “neutral” rating in a research report on Tuesday, November 5th. Finally, JPMorgan Chase & Co. raised their price target on TG Therapeutics from $30.00 to $43.00 and gave the company an “overweight” rating in a research report on Monday, November 25th. Two analysts have rated the stock with a hold rating and five have issued a buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $40.67.

TG Therapeutics Stock Down 0.6 %

Shares of NASDAQ:TGTX opened at $34.80 on Monday. The company has a market capitalization of $5.42 billion, a P/E ratio of -347.97 and a beta of 2.19. The stock’s fifty day simple moving average is $26.59 and its 200-day simple moving average is $22.29. TG Therapeutics, Inc. has a 52-week low of $12.37 and a 52-week high of $36.84. The company has a quick ratio of 3.91, a current ratio of 4.59 and a debt-to-equity ratio of 1.27.

TG Therapeutics (NASDAQ:TGTX) last released its quarterly earnings results on Monday, November 4th. The biopharmaceutical company reported $0.02 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.03 by ($0.01). The firm had revenue of $83.90 million for the quarter, compared to analyst estimates of $81.68 million. TG Therapeutics had a negative return on equity of 8.32% and a negative net margin of 5.42%. TG Therapeutics’s revenue for the quarter was down 49.4% on a year-over-year basis. During the same period in the prior year, the business earned $0.73 earnings per share. As a group, equities research analysts forecast that TG Therapeutics, Inc. will post 0.17 earnings per share for the current fiscal year.

About TG Therapeutics

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.